No Data
Clearmind Medicine To Develop Novel Intranasal Formulation With Polyrizon
Clearmind Medicine Announced That It Has Signed A Non-binding Letter Of Intent With Polyrizon To Develop A Novel Intranasal Formulation For Its Psychedelic-based Treatment Applications
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
Polyrizon Signs Non– Binding LOI With A Biotech Company Focused On Psychedelic-derived Therapeutics, To Develop A Novel Intranasal Formulation For Psychedelic-Based Treatment Applications
Express News | Polyrizon Signs Non– Binding Loi to Expand Its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
Polyrizon Signs Non– Binding LOI to Expand Its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
